<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this work, effects of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> on <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, clonal progenitor growth, cytokine production, and NF-κB expression in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with cytopenias requiring transfusion support are examined </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="52717">Bortezomib</z:chebi> <z:mp ids='MP_0006042'>increased apoptosis</z:mp> in marrow mononuclear cells but had no effects on CFU-GM, BFU-E, or CFU-L content </plain></SENT>
<SENT sid="2" pm="."><plain>No consistent effects on NF-κB activation in vivo were noted </plain></SENT>
<SENT sid="3" pm="."><plain>To further define the role of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, we examined it in combination with several targeted agents and chemotherapeutic agents in vitro </plain></SENT>
<SENT sid="4" pm="."><plain>Combinations with <z:chebi fb="0" ids="30621">arsenic trioxide</z:chebi>, <z:chebi fb="0" ids="50924">sorafenib</z:chebi>, and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> demonstrated synergistic in vitro effects in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell lines </plain></SENT>
</text></document>